Skip to main content

Table 2 Baseline demographic and clinical variables and baseline domain scores associated with overall survival

From: Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment

Variable Univariatea Multivariatea
HR (95 % CI) P HR (95 % CI) P
Baseline characteristics
Age <70 y (vs. ≥70 y) 0.603 (0.349–1.258) 0.208   
Sex, male (vs. female) 0.544 (0.254–1.167) 0.118   
HCV infection (vs. other etiology) 1.138 (0.610–0.122) 0.684   
Child Pugh = 5 (vs. ≥6) 0.419 (0.227–0.812) 0.009   
TMN stage III (vs. IV) 0.695 (0.371–1.304) 0.257   
Vascular invasion - (vs. +) 0.475 (0.204–0.945) 0.034   
Tumor size <50 mm (vs. ≥50 mm) 0.831 (0.441–1.567) 0.567   
Previous curative therapy: Yes (vs. No) 0.255 (0.129–0.504) <0.001 0.235 (0.116–0.477) <0.001
AFP <100 (vs. ≥100) 0.893 (0.473–1.686) 0.726   
DCP <1000 (vs. ≥1000) 0.548 (0.280–1.070) 0.078   
Initial dose of sorafenib 800 mg (vs. <800 mg) 1.137 (0.611–2.115) 0.686   
Treatment duration ≥5 months (vs. <5) 0.608 (0.325–1.138) 0.120   
HRQOL domain scores ≥40b:
Physical functioning 0.529 (0.278–1.008) 0.053 0.479 (0.245–0.935) 0.031
Role physical 0.595 (0.314–1.127) 0.111   
Bodily pain 1.686 (0.772–3.676) 0.190   
General health 1.331 (0.644–2.755) 0.440   
Vitality 0.842 (0.383–1.848) 0.669   
Social functioning 0.833 (0.411–1.684) 0.610   
Role emotional 0.957 (0.473–1.938) 0.904   
Mental health 2.053 (0.893–4.717) 0.090   
  1. HR hazard ratio, CI confidence interval, HCV hepatitis C virus, TNM tumor-node-metastasis, AFP alpha fetoprotein, DCP des-gamma-carboxy prothrombin, HRQOL health related quality of life
  2. aCox proportional hazards regression analysis
  3. bAll domain scores are relative to scores <40
  4. All variables with P values <0.06 in the univariate analysis were included in the multivariate analysis